Cargando…

Looking Into the Crystal Ball: Predicting Non-response to Ursodeoxycholic Acid in Primary Biliary Cholangitis

Detalles Bibliográficos
Autores principales:	Zimmer, Vincent, Lammert, Frank
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2016
Materias:	Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5233803/ https://www.ncbi.nlm.nih.gov/pubmed/28007481 http://dx.doi.org/10.1016/j.ebiom.2016.12.008

Ejemplares similares

Predictive Model of Ursodeoxycholic Acid Treatment Response in Primary Biliary Cholangitis
por: Shu, Yanyun, et al.
Publicado: (2021)

External validation of the United Kingdom‐primary biliary cholangitis risk scores of patients with primary biliary cholangitis treated with ursodeoxycholic acid
por: Cheung, Angela C., et al.
Publicado: (2018)

Fibrates for the Treatment of Primary Biliary Cholangitis Unresponsive to Ursodeoxycholic Acid: An Exploratory Study
por: Cançado, Guilherme Grossi Lopes, et al.
Publicado: (2022)

Evaluation of the United Kingdom‐primary biliary cholangitis and global primary biliary cholangitis group prognostic models for primary biliary cholangitis patients treated with ursodeoxycholic acid in the U.S. population
por: Alomari, Mohammad, et al.
Publicado: (2019)

Combination therapy of obeticholic acid and ursodeoxycholic acid in patients with primary biliary cholangitis who respond incompletely to ursodeoxycholic acid: a systematic review
por: Li, Xuan, et al.
Publicado: (2020)

Bacterial and metabolic phenotypes associated with inadequate response to ursodeoxycholic acid treatment in primary biliary cholangitis
por: Martinez-Gili, Laura, et al.
Publicado: (2023)

Prediction and evaluation of high-risk patients with primary biliary cholangitis receiving ursodeoxycholic acid therapy: an early criterion
por: Yang, Chunmei, et al.
Publicado: (2022)

Number needed to treat with ursodeoxycholic acid therapy to prevent liver transplantation or death in primary biliary cholangitis
por: Harms, Maren H, et al.
Publicado: (2020)

Combination therapy of ursodeoxycholic acid and glucocorticoid and (or) immunosuppressant in patients with primary biliary cholangitis: A meta-analysis
por: Wang, Zi-Long, et al.
Publicado: (2022)

A randomized, controlled trial on fenofibrate in primary biliary cholangitis patients with incomplete response to ursodeoxycholic acid
por: Li, Chunlei, et al.
Publicado: (2022)

Effectiveness of bezafibrate and ursodeoxycholic acid in patients with primary biliary cholangitis: a meta-analysis of randomized controlled trials
por: Agrawal, Rohit, et al.
Publicado: (2019)

A 60-Year-Old Woman with Primary Biliary Cholangitis and Crohn’s Ileitis Following the Suspension of Ursodeoxycholic Acid
por: Romeo, Mario, et al.
Publicado: (2022)

Efficacy and safety of fenofibrate addition therapy in patients with cirrhotic primary biliary cholangitis with incomplete response to ursodeoxycholic acid
por: Ding, Dawei, et al.
Publicado: (2022)

Efficacy of ursodeoxycholic acid for primary biliary cholangitis: Experience from a tertiary care centre in Saudi Arabia
por: AlWabel, Ahmed H, et al.
Publicado: (2022)

Acute Bacterial Cholangitis
por: Zimmer, Vincent, et al.
Publicado: (2015)

Concomitant Sjögren's Syndrome Was Not Associated with a Poorer Response or Outcomes in Ursodeoxycholic Acid-Treated Patients with Primary Biliary Cholangitis
por: Ni, Ping, et al.
Publicado: (2019)

Predictors for incomplete response to ursodeoxycholic acid in primary biliary cholangitis. Data from a national registry of liver disease
por: Cortez‐Pinto, Helena, et al.
Publicado: (2021)

Treatment of ursodeoxycholic acid with glucocorticoids and immunosuppressants may improve the long-term survival rate in primary biliary cholangitis patients
por: Wang, Zi-Long, et al.
Publicado: (2022)

Prognostic Factors for Transplant-Free Survival and Validation of Prognostic Models in Chinese Patients with Primary Biliary Cholangitis Receiving Ursodeoxycholic Acid
por: Cheung, Ka-Shing, et al.
Publicado: (2017)

Ursodeoxycholic Acid at 18–22 mg/kg/d Showed a Promising Capacity for Treating Refractory Primary Biliary Cholangitis
por: Xiang, Xinyu, et al.
Publicado: (2021)

Liver transplant‐free survival according to alkaline phosphatase and GLOBE score in patients with primary biliary cholangitis treated with ursodeoxycholic acid
por: de Veer, Rozanne C., et al.
Publicado: (2022)

Ursodeoxycholic Acid Treatment–Induced GLOBE Score Changes Are Associated With Liver Transplantation-Free Survival in Patients With Primary Biliary Cholangitis
por: de Veer, Rozanne C., et al.
Publicado: (2023)

Clinical Outcomes and Validation of Ursodeoxycholic Acid Response Scores in Patients with Korean Primary Biliary Cholangitis: A Multicenter Cohort Study
por: Chang, Jong-In, et al.
Publicado: (2023)

High neutrophil-lymphocyte ratio indicates a worse response to ursodeoxycholic acid in primary biliary cholangitis: a retrospective cohort study
por: Zhu, Huiling, et al.
Publicado: (2023)

A decline of LAMP- 2 predicts ursodeoxycholic acid response in primary biliary cirrhosis
por: Wang, Lu, et al.
Publicado: (2015)

A Prospective Trial of Withdrawal and Reinstitution of Ursodeoxycholic Acid in Pediatric Primary Sclerosing Cholangitis
por: Black, Dennis D., et al.
Publicado: (2019)

Obeticholic acid for primary biliary cholangitis
Publicado: (2020)

Obeticholic Acid for Primary Biliary Cholangitis
por: Floreani, Annarosa, et al.
Publicado: (2022)

Therapeutic and immunological interventions in primary biliary cholangitis: from mouse models to humans
por: Tanaka, Atsushi, et al.
Publicado: (2017)

A randomized crossover trial to assess therapeutic efficacy and cost reduction of acid ursodeoxycholic manufactured by the university hospital for the treatment of primary biliary cholangitis
por: Nakano, Larissa Akeme, et al.
Publicado: (2020)

Efficacy and safety of fenofibrate add-on therapy in patients with primary biliary cholangitis refractory to ursodeoxycholic acid: A retrospective study and updated meta-analysis
por: Guoyun, Xuan, et al.
Publicado: (2022)

Curative effect of anti-fibrosis Chinese patent medicines combined with ursodeoxycholic acid for primary biliary cholangitis: A systematic review and meta-analysis
por: Bi, Yufei, et al.
Publicado: (2023)

Autoimmune biliary diseases: primary biliary cholangitis and primary sclerosing cholangitis
por: Sarcognato, Samantha, et al.
Publicado: (2021)

Predicting Risk in Primary Biliary Cholangitis
por: Cho, Eun Ju
Publicado: (2023)

Ursodeoxycholate inhibits mast cell activation and reverses biliary injury and fibrosis in Mdr2(−/−) mice and human primary sclerosing cholangitis
por: Meng, Fanyin, et al.
Publicado: (2018)

NI‐0801, an anti‐chemokine (C‐X‐C motif) ligand 10 antibody, in patients with primary biliary cholangitis and an incomplete response to ursodeoxycholic acid
por: de Graaf, Kathy L., et al.
Publicado: (2018)

Predicting Outcomes in Acute Kidney Injury Survivors: Searching for the Crystal Ball
por: Beaubien-Souligny, William, et al.
Publicado: (2019)

Cholangitis‐related biliary pneumatosis cysts in the dawning era of routine direct endoscopic visualization of biliary diseases
por: Zimmer, Vincent
Publicado: (2022)

Ursodeoxycholic Acid Improves Bilirubin but Not Albumin in Primary Biliary Cirrhosis: Further Evidence for Nonefficacy
por: Tsochatzis, Emmanuel A., et al.
Publicado: (2013)

A Systems Model for Ursodeoxycholic Acid Metabolism in Healthy and Patients With Primary Biliary Cirrhosis
por: Zuo, P, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_rca9pg5dksaj4b4trenrgu6iki